GlassScriptPhysician profile
Maxine A Lipon
NPI 1598984387
$1,498.77
in general payments reported to CMS, 2019-2025
21 companies · $464 in 2025
The $464 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82.07 · 2020: $34.53 · 2022: $77.56 · 2023: $384 · 2024: $457 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,304.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $382.04 | 2023-2025 | |
| Glaxosmithkline, LLC. | $250.08 | 2022-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $136.48 | 2022-2025 | Jardiance, Zepbound, Emgality |
| Astrazeneca Pharmaceuticals LP | $94.86 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Exact Sciences Corporation | $62.23 | 2023-2024 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $59.80 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $57.60 | 2024-2025 | Rexulti |
| Novo Nordisk INC | $50.87 | 2023-2024 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.96 | 2019-2023 | Jardiance |
| Amgen INC. | $44.30 | 2023-2025 | Prolia, Evenity, Otezla |
| Pfizer INC. | $43.42 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $42.21 | 2023-2025 | Vaxneuvance, Gardasil 9, Pneumovax 23 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.82 | 2023-2025 | Caplyta |
| Dexcom, INC. | $37.30 | 2023-2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $31.50 | 2022-2023 | Myrbetriq |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $24.05 | 2025 | Skyclarys |
| Indivior INC. | $23.26 | 2024 | Sublocade |
| Amarin Pharma, INC. | $21.96 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.99 | 2024 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $17.47 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $12.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maxine Lipon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.